# Denali 股價上漲 4.2%，至 21.86 美元。

*biotech · news · 2026-03-25 · Newsmax*

## Key points

- FDA 已批准 Denali Therapeutics 的 Avlayah 用於治療 Hunter 綜合症。
- 這是 Denali Therapeutics 在美國市場的首個藥品批准。
- Avlayah 是一種針對 iduronate-2-sulfatase 缺乏症的酵素替代療法。
- Denali 股價在 FDA 批准公告後上漲了 4.2%。

The Food and Drug Administration has approved Denali Therapeutics' treatment for a rare genetic disorder, the regulator said on Wednesday. The approval marks the first regulatory green light for the drugmaker in the U.S. Denali shares were up 4.2% at $21.86. Marketed as Avlayah, the enzyme replacement therapy is aimed at treating Hunter syndrome, a rare genetic disorder that leads to the buildup of certain sugar molecules in the brain and body. The disorder is caused by a deficiency of the enzyme iduronate-2-sulfatase, which prevents the body from breaking down large sugar molecules called glycosaminoglycans.

**Countries:** United States

[Read the full story on Newsmax](https://www.newsmax.com/politics/fda-denali-therapeutics-genetic-disorders/2026/03/25/id/1250750/)

---

Canonical: https://newsio.io/zh-TW/n/0a65d66b-521e-4bfa-8810-e688c5e21029/denali-4-2-21-86
Summarized by Newsio from Newsmax. https://newsio.io/how-it-works